Inspire Investing’s Nektar Therapeutics NKTR Stock Holding History

Inspire Investing’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47	Hold	1	–	–	﹤0.01%	1238
2026 Q1	$48	Buy	+1	New	+$57	﹤0.01%	1075
2025 Q4	–	Hold	0	–	–	–	1104
2023 Q3	–	Sell	-36,770	Closed	-$317K	–	858
2023 Q2	$317K	Buy	36,770 +10,520	+40%	+$112K	0.04%	432
2023 Q1	$277K	Buy	26,250 +19,217	+273%	+$581K	0.04%	422
2022 Q4	$238K	Buy	7,033 +2,715	+63%	+$131K	0.03%	369
2022 Q3	$207K	Buy	4,318 +592	+16%	+$35.2K	0.03%	520
2022 Q2	$212K	Buy	3,726 +797	+27%	+$50.3K	0.03%	558
2022 Q1	$237K	Buy	2,929 +1,731	+144%	+$256K	0.03%	430
2021 Q4	$243K	Buy	1,198 +353	+42%	+$76.6K	0.03%	765
2021 Q3	$228K	Buy	+845	New	+$203K	0.03%	636
2020 Q2	–	Sell	-1	Closed	–	–	636
2020 Q1	$0	Buy	+1	New	+$309	﹤0.01%	771
2018 Q1	–	Sell	-197	Closed	-$177K	–	522
2017 Q4	$177K	Buy	+197	New	+$117K	0.15%	146

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Inspire Investing's NKTR Position: Q2 2026 in Review

Inspire Investing held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 1 share worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

Inspire Investing first reported a position in NKTR in Q4 2017 and has held it in 12 quarters since. The position peaked at $317K in Q2 2023. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

Inspire Investing held 1 share of Nektar Therapeutics worth $47 as of Q2 2026.
Inspire Investing left its Nektar Therapeutics share count unchanged in Q2 2026.
Nektar Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q2 2026, its #1238 holding.
Inspire Investing first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 12 quarters since.
Inspire Investing's Nektar Therapeutics position peaked at $317K in Q2 2023.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.